Cvfg LLC Acquires Shares of 67,450 Aurinia Pharmaceuticals Inc $AUPH

Cvfg LLC acquired a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 67,450 shares of the biotechnology company’s stock, valued at approximately $1,000,000.

Several other hedge funds also recently made changes to their positions in AUPH. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $32,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Aurinia Pharmaceuticals in the third quarter valued at about $48,000. Kemnay Advisory Services Inc. acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at about $82,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Aurinia Pharmaceuticals by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 1,318 shares in the last quarter. Finally, Cornerstone Investment Partners LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $178,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Transactions at Aurinia Pharmaceuticals

In other news, CEO Kevin Tang acquired 343,620 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $15.28 per share, with a total value of $5,250,513.60. Following the completion of the acquisition, the chief executive officer owned 12,838,101 shares in the company, valued at $196,166,183.28. This trade represents a 2.75% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders acquired 814,606 shares of company stock worth $12,455,129 over the last ninety days. Insiders own 12.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AUPH shares. Weiss Ratings downgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Zacks Research raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Aurinia Pharmaceuticals Trading Up 0.1%

Shares of Aurinia Pharmaceuticals stock opened at $16.23 on Thursday. The company has a 50-day moving average of $15.98 and a two-hundred day moving average of $15.37. Aurinia Pharmaceuticals Inc has a 12-month low of $7.62 and a 12-month high of $19.25. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08. The stock has a market cap of $2.09 billion, a PE ratio of 7.48 and a beta of 1.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.18 by $0.07. The business had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%. On average, research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.